Drug Discovery Featured Articles & Applications

31. Redesigning Oncology Trials Around Tumor Vulnerability: The Rise of WEE1 And DDR Strategies 9/8/2025

    As clinical progress with DNA damage response (DDR) continues to evolve, research must respond with adaptive models, smarter combinations, and biomarker-informed patient selection.

32. Targeting GRIN Genes In Drug Development To Treat Neurodevelopment Disorders 8/28/2025

    The ability to precisely control the activity of NMDA receptors could play a role in the treatment of a range of neurodevelopmental disorders. We caught up with GRIN Therapeutics' chief medical officer to discuss drug development.

33. Can America's Retreat On mRNA Be Europe's Opportunity? 8/28/2025

    With HHS winding down mRNA vaccine development under BARDA, could Europe seize the opportunity to lead in mRNA innovation? Exploring the policy shift's implications.

34. The OBBBA: Biopharmas Unlock R&D Expensing, Global Tax Efficiencies 8/28/2025

    Biopharma innovators may soon see major tax breaks thanks to the One Big Beautiful Bill Act (OBBBA). The new legislation introduces targeted tax incentives designed to strengthen domestic R&D and capital investment.

35. AI Plus The Scientific Method Might Reinvent Drug Discovery 8/26/2025

    In the absence of good data, clear hypotheses, and experimental feedback, AI’s outputs can quickly become unreliable. The solution lies in integrating AI and the scientific method.

36. Developing Interleukin-2 For Cell Therapies: Key Considerations 8/20/2025

    By promoting cell expansion, survival, and functionality, interleukins help optimize therapeutic outcomes in cancer immunotherapy and regenerative medicine. Let’s look closer and compare ex vivo and in vivo approaches.

37. Unlocking The Pharmacological Potential Of Antibodies 8/20/2025

    Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains the company's Functional Antibody Selection Technology (FAST) platform and its approach to developing a pipeline of G protein-coupled receptor (GPCR) mAbs.

38. Weight Of Evidence Assessments For Carcinogenicity Studies: An Overview 8/20/2025

    Carcinogenicity assessments often rely heavily on two-year rodent bioassays. The weight of evidence (WoE) approach seeks to streamline this process, combining thorough science with regulatory practicality.

39. Advancing CAR T Cell Therapy with Logic Gate Engineering 8/19/2025

    Logic gating applies Boolean logic principles to CAR T cell design to improve precision and minimize collateral damage.

40. Oligos Step Into The Spotlight: A Growing Force In Genetic Medicine 8/18/2025

    Oligonucleotide therapeutics are experiencing a new wave of momentum. As the science evolves and the market opportunity expands, the landscape is poised for continued growth and diversification.